Balance Therapeutics

Balance Therapeutics

Facts & Stats

  • Developmental intellectual disabilities including Down Syndrome, are characterized by an IQ <70 and by deficits in academic, adaptive and interpersonal skills.There are about 250,000 people with Down syndrome in the US.
  • Balance Therapeutics’ Phase 1b/2a clinical trial DS102 for cognitive impairment in Down syndrome is currently being conducted in Australia and will enroll 90 people with Down syndrome age 13 to 35. 
  • BTD-001 has had decades of safe human experience and has served as rescue therapy for barbiturate overdosing, was a component in respiratory medications, and was used to treat senile dementia.

Adamas

Adamas

Facts & Stats

  • Adamas went public in April 2014, trading on the Nasdaq stock market under the ticker, ‘ADMS’.
  • Adamas’ diversified business model provides the company with the flexibility to develop products on its own or in partnership with others.
  • If approved, Adamas plans to commercialize ADS-5102 and potentially other wholly-owned product candidates through a targeted CNS commercial organization.

 

Syndicate content